-
公开(公告)号:US20060169199A1
公开(公告)日:2006-08-03
申请号:US11326723
申请日:2006-01-05
摘要: The invention provides a method for crystallization and purification of tacrolimus that includes the step of providing a combination of a macrolide and a polar solvent, dopolar aprotic solvent, or hydrocarbon solvent at pH of 7 or above. The invention also provides a novel crystalline form of tacrolimus.
摘要翻译: 本发明提供了他克莫司的结晶和纯化方法,该方法包括在pH7或更高的pH值下提供大环内酯和极性溶剂,多酚非质子溶剂或烃溶剂的组合的步骤。 本发明还提供了他克莫司的新型结晶形式。
-
公开(公告)号:US20060135548A1
公开(公告)日:2006-06-22
申请号:US11293747
申请日:2005-12-01
IPC分类号: A61K31/4745 , C07D491/14
CPC分类号: C07D498/18 , A61K9/145 , A61K9/1688 , A61K31/4745 , C07D491/14 , C07H19/01
摘要: The present invention provides processes for crystallization of macrolides, specifically pimecrolimus and tacrolimus.
摘要翻译: 本发明提供大环内酯,特别是吡美莫司和他克莫司的结晶方法。
-
公开(公告)号:US07645876B2
公开(公告)日:2010-01-12
申请号:US11293747
申请日:2005-12-01
IPC分类号: C07D498/18
CPC分类号: C07D498/18 , A61K9/145 , A61K9/1688 , A61K31/4745 , C07D491/14 , C07H19/01
摘要: The present invention provides processes for crystallization of macrolides, specifically pimecrolimus and tacrolimus.
摘要翻译: 本发明提供大环内酯,特别是吡美莫司和他克莫司的结晶方法。
-
公开(公告)号:US20060154953A1
公开(公告)日:2006-07-13
申请号:US11326724
申请日:2006-01-05
IPC分类号: A61K31/4745
CPC分类号: C07D498/18 , A61K31/4745
摘要: The present invention provides amorphous tacrolimus in a free drug particulate form. Also provided are methods for preparing amorphous tacrolimus, and a tablet containing amorphous tacrolimus.
摘要翻译: 本发明提供游离药物颗粒形式的无定形他克莫司。 还提供了制备无定形他克莫司的方法和含有无定形他克莫司的片剂。
-
公开(公告)号:US07439252B2
公开(公告)日:2008-10-21
申请号:US11293286
申请日:2005-12-01
IPC分类号: C07D498/18 , A61K31/395 , A61P31/04
CPC分类号: C07D498/18 , A61K9/145 , A61K9/1688 , A61K31/4745 , C07D491/14 , C07H19/01
摘要: The present invention provides novel crystalline forms of ascomycin as well as processes for the preparation thereof and pharmaceutical compositions comprising such crystalline forms of ascomycin.
摘要翻译: 本发明提供新颖的子囊霉素结晶形式,以及其制备方法和包含这种结晶形式的子囊霉素的药物组合物。
-
公开(公告)号:US20060194984A1
公开(公告)日:2006-08-31
申请号:US11351468
申请日:2006-02-09
申请人: Vilmos Keri , Edit Nagyne Arvai , Zoltan Czovek , Adrienne Kovacsne-Mezei , Istvan Katai , Csilla Nemethne Racz
发明人: Vilmos Keri , Edit Nagyne Arvai , Zoltan Czovek , Adrienne Kovacsne-Mezei , Istvan Katai , Csilla Nemethne Racz
IPC分类号: C07C69/66
摘要: The invention encompasses a new crystalline form of pravastatin sodium characterized by X-ray powder diffraction peaks at 3.3, 3.9, 5.4, 6.4, 16.8, and 17.5 degrees two-theta, ±0.1 degrees two-theta and to methods of forming the crystalline form of the present invention and methods of making pravastatin Form B and Form D.
摘要翻译: 本发明包括普伐他汀钠的新结晶形式,其特征在于在3.3,3.9,5.4,6.4,16.8和17.5度2θ,±0.1度2θ的X射线粉末衍射峰和形成结晶形式的方法 的本发明和制备普伐他汀形式B和形式D的方法。
-
公开(公告)号:US20060155119A1
公开(公告)日:2006-07-13
申请号:US11293286
申请日:2005-12-01
IPC分类号: C07D267/22
CPC分类号: C07D498/18 , A61K9/145 , A61K9/1688 , A61K31/4745 , C07D491/14 , C07H19/01
摘要: The present invention provides novel crystalline forms of ascomycin as well as processes for the preparation thereof and pharmaceutical compositions comprising such crystalline forms of ascomycin.
摘要翻译: 本发明提供新颖的子囊霉素结晶形式,以及其制备方法和包含这种结晶形式的子囊霉素的药物组合物。
-
公开(公告)号:US07488758B2
公开(公告)日:2009-02-10
申请号:US11133722
申请日:2005-05-20
申请人: Valeriano Merli , Silvia Mantovani , Stefano Bianchi , Paola Daverio , Angelo Spreafico , Judith Aronhime , Adrienne Kovacsne-Mezei
发明人: Valeriano Merli , Silvia Mantovani , Stefano Bianchi , Paola Daverio , Angelo Spreafico , Judith Aronhime , Adrienne Kovacsne-Mezei
IPC分类号: A61K31/135 , C07C211/00
CPC分类号: C07C229/38 , C07C215/60 , C07C217/48 , C07C227/34
摘要: The invention is directed to levalbuterol HCl Form B and methods of making the same.
摘要翻译: 本发明涉及盐酸左沙利度胺HCl及其制备方法。
-
公开(公告)号:US20080312471A1
公开(公告)日:2008-12-18
申请号:US12228317
申请日:2008-08-11
申请人: Judith Aronhime , Stefano Bianchi , Eugenio Castelli , Paola Daverio , Silvia Mantovani , Adrienne Kovacsne-Mezei
发明人: Judith Aronhime , Stefano Bianchi , Eugenio Castelli , Paola Daverio , Silvia Mantovani , Adrienne Kovacsne-Mezei
IPC分类号: C07C211/01
CPC分类号: C07C217/48
摘要: The present invention provides novel crystalline polymorph forms of atomoxetine hydrochloride denominated Forms B and C and methods for their preparation, as well as methods for the preparation of Form A. The present invention provides pharmaceutical compositions that comprise atomoxetine hydrochloride Form B, Form C, or mixtures thereof that can be used to treat attention deficit/hyperactivity disorder.
摘要翻译: 本发明提供了以盐酸阿托西汀形式B和C的新型结晶多晶型形式及其制备方法,以及制备形式A的方法。本发明提供药物组合物,其包含盐酸阿托西汀形式B,C型或 可用于治疗注意力缺陷/多动障碍的混合物。
-
公开(公告)号:US07439373B2
公开(公告)日:2008-10-21
申请号:US11186560
申请日:2005-07-20
申请人: Sandor Molnar , Csaba Szabo , Tivadar Tamas , Janos Hajko , Adrienne Kovacsne-Mezei , Judith Aronhime
发明人: Sandor Molnar , Csaba Szabo , Tivadar Tamas , Janos Hajko , Adrienne Kovacsne-Mezei , Judith Aronhime
IPC分类号: C07D307/00 , C07D413/00
CPC分类号: C07D307/83 , A61K31/365 , C07D307/88
摘要: Provided are crystalline mycophenolate sodium forms and processes for their preparation.
摘要翻译: 提供结晶霉酚酸钠形式及其制备方法。
-
-
-
-
-
-
-
-
-